# US 2025/0146020 A1 · Stable Cell Lines for Inducible Production of rAAV Virions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0146020 A1
- Document ID: US20250146020A1
- Status: Published application
- Kind: A1
- Application number: 18/750,819
- Filed: 2024-06-21
- Published: 2025-05-08
- Earliest claimed: 2020-07-30
- Applicants: Shape Therapeutics Inc.
- Inventors: Kenneth Prentice; Sandhya Pande
- Web page: https://patentgrep.com/patent/US20250146020A1

## CPC

- C12N 15/8645: {Adeno-associated virus}
- C07K 14/005: from viruses
- C12N 15/85: for animal cells
- C12N 15/86: Viral vectors
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2750/14152: relating to complementing cells and packaging systems for producing virus or viral particles
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Described herein are polynucleotide constructs and stable cell lines for inducible production of rAAV virions within which are packaged a payload polynucleotide.

## Claims

### Claim at position 1

1-157. (canceled)

### Claim 158

A polynucleotide, comprising, from 5′ to 3′:
a first sequence comprising:
a first promoter sequence operably linked to a first part of an AAV Rep coding sequence,
a 5′ splice site,
a first intron,
an excisable element comprising, from 5′ to 3′, a first recombination site, a first 3′ splice site, a coding sequence comprising a stop signaling sequence, and a second recombination site,
a second intron, and
a second 3′ splice site; and
a second sequence comprising a second part of the AAV Rep coding sequence, wherein the first promoter is not operably linked to the second sequence in the absence of a recombination event between the first recombination site and the second recombination site and is operably linked to the second sequence following a recombination event between the first recombination site and the second recombination site.

### Claim 159 (depends on 158)

The polynucleotide of claim 158, comprising a third sequence comprising an AAV Cap coding sequence, wherein the second sequence comprises a second promoter that is operably linked to the third sequence.

### Claim 160 (depends on 158)

The polynucleotide of claim 158, wherein the 5′ splice site is a rabbit beta globin 5′ splice site, and the first 3′ splice site and the second 3′ splice site are each a rabbit beta globin 3′ splice site.

### Claim 161 (depends on 158)

The polynucleotide of claim 158, wherein the first recombination site is a first lox sequence and the second recombination site is a second lox sequence.

### Claim 162 (depends on 161)

The polynucleotide of claim 161, wherein the first lox sequence is a first loxP sequence and the second lox sequence is a second loxP sequence.

### Claim 163 (depends on 158)

The polynucleotide of claim 158, wherein the first recombination site is a first flippase recognition target (FRT) site and the second recombination site is a second FRT site.

### Claim 164 (depends on 158)

The polynucleotide of claim 158, wherein the stop signaling sequence is a termination sequence of the coding sequence comprising a stop signaling sequence or is a polyA sequence.

### Claim 165 (depends on 158)

The polynucleotide of claim 158, wherein the coding sequence comprising a stop signaling sequence encodes a detectable marker or a selectable marker.

### Claim 166 (depends on 158)

The polynucleotide of claim 158, wherein the coding sequence comprising a stop signaling sequence encodes a detectable marker comprising a luminescent marker or a fluorescent marker.

### Claim 167 (depends on 158)

The polynucleotide of claim 158, wherein the excisable element is excisable by a recombinase capable of inducing the recombination event between the first recombination site and the second recombination site.

### Claim 168 (depends on 167)

The polynucleotide of claim 167, wherein the recombinase is a Cre recombinase or a Flippase recombinase.

### Claim 169 (depends on 167)

The polynucleotide of claim 167, wherein the recombinase is an inducible recombinase.

### Claim 170 (depends on 169)

The polynucleotide of claim 169, wherein the inducible recombinase is a Cre recombinase fused to an estrogen response (ER) element for translocating to the nucleus in the presence of a triggering agent that is tamoxifen.

### Claim 171 (depends on 158)

The polynucleotide of claim 158, wherein the AAV Rep coding sequence encodes Rep polypeptides comprising Rep78, Rep68, Rep52, and Rep40.

### Claim 172 (depends on 159)

The polynucleotide of claim 159, wherein the AAV Cap coding sequence encodes AAV capsid proteins comprising VP1, VP2, and VP3.

### Claim 173 (depends on 158)

The polynucleotide of claim 158, comprising a fourth sequence encoding for a selectable marker under the control of a constitutive promoter.

### Claim 174 (depends on 173)

The polynucleotide of claim 173, wherein the selectable marker is a mammalian cell selection element.

### Claim 175 (depends on 174)

The polynucleotide of claim 174, wherein the mammalian cell selection element is an auxotrophic selection element or an antibiotic resistance protein.

### Claim 176 (depends on 159)

The polynucleotide of claim 159, wherein:
the AAV Rep coding sequence encodes Rep polypeptides comprising Rep78, Rep68, Rep52, and Rep40; and
the AAV Cap coding sequence encodes AAV capsid proteins comprising VP1, VP2, and VP3.

### Claim 177 (depends on 176)

The polynucleotide of claim 176, wherein the excisable element is excisable by a recombinase capable of inducing the recombination event between the first recombination site and the second recombination site, wherein the recombinase is a Cre recombinase fused to an estrogen response (ER) element for translocating to the nucleus in the presence of a triggering agent that is tamoxifen.

### Claim 178

A polynucleotide, comprising:
a first sequence comprising an inducible promoter operably linked to a first excisable element comprising a sequence encoding a recombinase that is flanked by a first recombination site and a second recombination site;
a second sequence comprising a first constitutive promoter operably linked to a sequence encoding an activator for inducing the inducible promoter in the presence of a first triggering agent; and
a third sequence encoding one or more AAV helper proteins, wherein the inducible promoter is not operably linked to the third sequence in the absence of a recombination event between the first recombination site and the second recombination site and is operably linked to the third sequence following a recombination event between the first recombination site and the second recombination site.

### Claim 179 (depends on 178)

The polynucleotide of claim 178, wherein the third sequence encoding one or more AAV helper proteins comprises a bicistronic open reading frame encoding E2a and E4.

### Claim 180 (depends on 178)

The polynucleotide of claim 178, wherein the inducible promoter is a tetracycline-response promoter element (TRE).

### Claim 181 (depends on 180)

The polynucleotide of claim 180, wherein the TRE comprises Tet operator (tetO) sequence concatemers fused to a minimal promoter.

### Claim 182 (depends on 180)

The polynucleotide of claim 180, wherein the activator is reverse tetracycline-controlled transactivator (rTA) comprising a Tet Repressor binding protein (TetR) fused to a VP16 transactivation domain, and the first triggering agent is tetracycline or doxycycline.

### Claim 183 (depends on 178)

The polynucleotide of claim 178, wherein the recombinase is an inducible recombinase.

### Claim 184 (depends on 183)

The polynucleotide of claim 183, wherein the inducible recombinase is a Cre recombinase fused to an estrogen response (ER) element for translocating to the nucleus in the presence of a second triggering agent that is tamoxifen.

### Claim 185 (depends on 178)

The polynucleotide of claim 178, comprising a fourth sequence comprising:
a first part of a second constitutive promoter and a second part of the second constitutive promoter separated by a second excisable element comprising a third recombination site and a fourth recombination site flanking a stuffer sequence; and
a VA-RNA coding sequence that is not operably linked to the second constitutive promoter in the absence of a recombination event between the third recombination site and the fourth recombination site and is operably linked to the second constitutive promoter following a recombination event between the third recombination site and the fourth recombination site.

### Claim 186 (depends on 178)

The polynucleotide of claim 178, comprising a fifth sequence encoding a selectable marker under the control of a third constitutive promoter.

### Claim 187 (depends on 178)

The polynucleotide of claim 178, wherein:
the inducible promoter is a TRE comprising tetO sequence concatemers fused to a minimal promoter;
the activator is rTA comprising a TetR fused to a VP16 transactivation domain;
the first triggering agent is tetracycline or doxycycline; and
the recombinase is a Cre recombinase fused to an ER element for translocating to the nucleus in the presence of a triggering agent that is tamoxifen.

### Claim 188 (depends on 187)

The polynucleotide of claim 187, comprising a fourth sequence comprising:
a first part of a second constitutive promoter and a second part of the second constitutive promoter separated by a second excisable element comprising a third recombination site and a fourth recombination site flanking a stuffer sequence; and
a VA-RNA coding sequence that is not operably linked to the second constitutive promoter in the absence of a recombination event between the third recombination site and the fourth recombination site and is operably linked to the second constitutive promoter following a recombination event between the third recombination site and the fourth recombination site, wherein the VA-RNA coding sequence encodes a transcriptionally dead VA-RNA.

### Claim 189 (depends on 159, 178)

A system for inducible AAV production, comprising:
the polynucleotide of claim 159; and
the polynucleotide of claim 178.

### Claim 190 (depends on 189)

The system of claim 189, further comprising a payload polynucleotide comprising a promoter operably linked to a payload sequence.

### Claim 191 (depends on 177, 187)

A system for inducible AAV production, comprising:
the AAV Rep/Cap polynucleotide of claim 177; and
the inducible helper polynucleotide of claim 187.

### Claim 192 (depends on 191)

The system of claim 191, further comprising a payload polynucleotide comprising a promoter operably linked to a payload sequence.
